AMH and breast carcinoma: Compared to breast cancer patients, those with hematologic malignancies had lower baseline AMH levels, as reported by Ferro et al., 2023: 2.19 ± 1.89 ng/ml (28); Ciccarone et al., 2020: 1.7 ng/ml (0.0-16.0 range) (23); and Ciccarone et al., 2023: 1.69 (0.0-16.0) (24).